ArticleInternal and emergency medicine2017
Italian intersociety consensus on DOAC use in internal medicine.
Article in Internal and emergency medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- Challenges in Patient Blood Management for Cardiac Surgery: A Narrative Review.Journal of clinical medicine · 2021Review
- Predictors of post-traumatic complication of mild brain injury in anticoagulated patients: DOACs are safer than VKAs.Internal and emergency medicine · 2021Observational
- Follow-up management of patients receiving direct oral anticoagulants.Internal and emergency medicine · 2021Observational
- Anticoagulation in patients with advanced liver disease: an open issue.Internal and emergency medicine · 2021Review
- Thrombosis centres and AVKs monitoring in COVID-19 pandemic.Internal and emergency medicine · 2020Article
- Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.Internal and emergency medicine · 2020Article
- The direct oral anticoagulants may also be effective against the risk of post-thrombotic syndrome.Internal and emergency medicine · 2020Article
- Determinants of health-related quality of life: a cross-sectional investigation in physician-managed anticoagulated patients using vitamin K antagonists.Health and quality of life outcomes · 2020Article
- Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Internal and emergency medicine · 2019Article
- Direct oral anticoagulants in factor VII deficiency patient.Internal and emergency medicine · 2019Article
- Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease.Internal and emergency medicine · 2019Article
- Direct oral anticoagulants in lipoprotein apheresis: handle with care.Internal and emergency medicine · 2019Article
- Optimal management of major bleeding on DOACs: not only reversal agents.Internal and emergency medicine · 2019Article
- Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer.Internal and emergency medicine · 2019Review
- A clinical conundrum: to measure or not measure direct oral anticoagulants before a surgery or procedure?Internal and emergency medicine · 2018Article
- Direct oral anticoagulants: what can we learn?Internal and emergency medicine · 2018Article
- Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban.Internal and emergency medicine · 2018Article
- Intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: significant differences between direct oral anticoagulants and vitamin K antagonists.Internal and emergency medicine · 2018Observational
- The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures.Internal and emergency medicine · 2018Review
- Drug plasma level measurement in management of severe bleeding during direct oral anticoagulant treatment: case report and perspective.Internal and emergency medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The direct oral anticoagulants (DOACs) are drugs used in clinical practice since 2009 for the prevention of stroke or systemic embolism in non-valvular atrial fibrillation, and for the treatment and secondary prevention of venous thromboembolism. The four DOACs, including the three factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) and one direct thrombin inhibitor (dabigatran) provide oral anticoagulation therapy alternatives to Vitamin K antagonists (VKAs). Despite their clear advantages, the DOACs require on the part of the internist a thorough knowledge of their pharmacokinetic and pharmacodynamic characteristics to ensure their correct use, laboratory monitoring and the appropriate management of adverse events. This document represents a consensus paper on the use of DOACs by representatives of three Italian scientific societies: the Italian Society of Internal Medicine (SIMI), the Federation of the Associations of Hospital Managers (FADOI), and the Society for the Study of Haemostasis and Thrombosis (SISET). This document formulates expert opinion guidance for pragmatic managing, monitoring and reversing the anticoagulant effect of DOACs in both chronic and emergency settings. This practical guidance may help the internist to create adequate protocols for patients hospitalized ion internal medicine wards, where patients are often elderly subjects affected by poly-morbidities and renal insufficiency, and, thus, require particular attention to drug-drug interactions and peri-procedural protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.